Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza for the Prevention of Recurrent Symptomatic Atrial Fibrillation
NCT00402363Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in Atrial fibrillation (AFib), sponsored by GSK. Started Nov 2006; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00402363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402363.